Sex differences in adverse events from systemic treatments for psoriasis : A decade of insights from the Swiss Psoriasis Registry (SDNTT)
© 2023 European Academy of Dermatology and Venereology..
BACKGROUND: Psoriasis is a disease that often requires prolonged systemic treatment. It is important to determine the safety of available therapies. There is currently little insight into sex-specific differences in the safety of systemic psoriasis therapies.
OBJECTIVES: To examine the real-world, long-term safety of systemic psoriasis therapies with sex stratification in drug-related adverse events (ADRs).
METHODS: Ten-year data from adults with moderate-to-severe psoriasis requiring systemic treatment (conventional systemic therapies [CST], biologics) were obtained from the Swiss psoriasis registry (SDNTT). ADRs were categorized according to the international terminology Medical Dictionary for Regulatory Activities (MedDRA). Safety was assessed by calculating event rates per 100 patient-years (PY). We used descriptive statistics for patient and disease characteristics, and binomial and t-tests to compare treatment groups and sex.
RESULTS: In total, 791 patients (290 females) were included with a mean age of 46 years. 358 (45%) received CSTs and 433 (55%) biologics; both groups had similar baseline characteristics except for more joint involvement in patients using biologics (26.86% vs. 14.8%, p < 0.0001). CSTs were associated with a 2.2-fold higher ADR rate (40.43/100 PY vs. 18.22/100 PY, p < 0.0001) and an 8.0-fold higher drug-related discontinuation rate than biologics (0.16/PY vs. 0.02/PY, p < 0.0001). Trends showed non-significant higher serious adverse event rates per 100 PY for biologics (8.19, CI 6.87-9.68) compared to CSTs (7.08, CI 5.39-9.13) (p = 0.3922). Sex stratification revealed a significantly higher overall ADR rate for all treatments in females (1.8-fold for CSTs [57.30/100 PY vs. 31.69/100 PY] and 2.0-fold for biologics [27.36/100 PY vs. 13.9/100 PY], p < 0.0001), and drug-related discontinuation rates for most CSTs in females.
CONCLUSION: Females were associated with a significantly higher rate of ADRs and drug-related discontinuation rates. Sex stratification should be taken into consideration when designing studies in the patient-tailored management of psoriasis.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:38 |
|---|---|
| Enthalten in: |
Journal of the European Academy of Dermatology and Venereology : JEADV - 38(2024), 4 vom: 01. März, Seite 719-731 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Verardi, Fabio [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 26.03.2024 Date Revised 26.03.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1111/jdv.19730 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM365756156 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM365756156 | ||
| 003 | DE-627 | ||
| 005 | 20240326235118.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/jdv.19730 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1348.xml |
| 035 | |a (DE-627)NLM365756156 | ||
| 035 | |a (NLM)38084852 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Verardi, Fabio |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Sex differences in adverse events from systemic treatments for psoriasis |b A decade of insights from the Swiss Psoriasis Registry (SDNTT) |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 26.03.2024 | ||
| 500 | |a Date Revised 26.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023 European Academy of Dermatology and Venereology. | ||
| 520 | |a BACKGROUND: Psoriasis is a disease that often requires prolonged systemic treatment. It is important to determine the safety of available therapies. There is currently little insight into sex-specific differences in the safety of systemic psoriasis therapies | ||
| 520 | |a OBJECTIVES: To examine the real-world, long-term safety of systemic psoriasis therapies with sex stratification in drug-related adverse events (ADRs) | ||
| 520 | |a METHODS: Ten-year data from adults with moderate-to-severe psoriasis requiring systemic treatment (conventional systemic therapies [CST], biologics) were obtained from the Swiss psoriasis registry (SDNTT). ADRs were categorized according to the international terminology Medical Dictionary for Regulatory Activities (MedDRA). Safety was assessed by calculating event rates per 100 patient-years (PY). We used descriptive statistics for patient and disease characteristics, and binomial and t-tests to compare treatment groups and sex | ||
| 520 | |a RESULTS: In total, 791 patients (290 females) were included with a mean age of 46 years. 358 (45%) received CSTs and 433 (55%) biologics; both groups had similar baseline characteristics except for more joint involvement in patients using biologics (26.86% vs. 14.8%, p < 0.0001). CSTs were associated with a 2.2-fold higher ADR rate (40.43/100 PY vs. 18.22/100 PY, p < 0.0001) and an 8.0-fold higher drug-related discontinuation rate than biologics (0.16/PY vs. 0.02/PY, p < 0.0001). Trends showed non-significant higher serious adverse event rates per 100 PY for biologics (8.19, CI 6.87-9.68) compared to CSTs (7.08, CI 5.39-9.13) (p = 0.3922). Sex stratification revealed a significantly higher overall ADR rate for all treatments in females (1.8-fold for CSTs [57.30/100 PY vs. 31.69/100 PY] and 2.0-fold for biologics [27.36/100 PY vs. 13.9/100 PY], p < 0.0001), and drug-related discontinuation rates for most CSTs in females | ||
| 520 | |a CONCLUSION: Females were associated with a significantly higher rate of ADRs and drug-related discontinuation rates. Sex stratification should be taken into consideration when designing studies in the patient-tailored management of psoriasis | ||
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Biological Factors |2 NLM | |
| 650 | 7 | |a Biological Products |2 NLM | |
| 700 | 1 | |a Maul, Lara Valeska |e verfasserin |4 aut | |
| 700 | 1 | |a Borsky, Kim |e verfasserin |4 aut | |
| 700 | 1 | |a Steinmann, Simona |e verfasserin |4 aut | |
| 700 | 1 | |a Rosset, Nina |e verfasserin |4 aut | |
| 700 | 1 | |a Pons, Hector Ortega |e verfasserin |4 aut | |
| 700 | 1 | |a Sorbe, Christina |e verfasserin |4 aut | |
| 700 | 1 | |a Yawalkar, Nikhil |e verfasserin |4 aut | |
| 700 | 1 | |a Micheroli, Raphael |e verfasserin |4 aut | |
| 700 | 1 | |a Egeberg, Alexander |e verfasserin |4 aut | |
| 700 | 1 | |a Thyssen, Jacob P |e verfasserin |4 aut | |
| 700 | 1 | |a Heidemeyer, Kristine |e verfasserin |4 aut | |
| 700 | 1 | |a Boehncke, Wolf-Henning |e verfasserin |4 aut | |
| 700 | 1 | |a Conrad, Curdin |e verfasserin |4 aut | |
| 700 | 1 | |a Cozzio, Antonio |e verfasserin |4 aut | |
| 700 | 1 | |a Pinter, Andreas |e verfasserin |4 aut | |
| 700 | 1 | |a Kündig, Thomas |e verfasserin |4 aut | |
| 700 | 1 | |a Navarini, Alexander A |e verfasserin |4 aut | |
| 700 | 1 | |a Maul, Julia-Tatjana |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of the European Academy of Dermatology and Venereology : JEADV |d 1997 |g 38(2024), 4 vom: 01. März, Seite 719-731 |w (DE-627)NLM091705932 |x 1468-3083 |7 nnns |
| 773 | 1 | 8 | |g volume:38 |g year:2024 |g number:4 |g day:01 |g month:03 |g pages:719-731 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/jdv.19730 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 38 |j 2024 |e 4 |b 01 |c 03 |h 719-731 | ||